Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis

Area of Science:

• Pediatric Gastroenterology and Hepatology
• Clinical Trial Endpoints
• Biomarker Research

Background:

• Primary sclerosing cholangitis (PSC) in children has slow-progressing adverse events, necessitating surrogate endpoints for clinical trials.
• Validated surrogate endpoints for pediatric PSC are currently lacking.
• Gamma glutamyltransferase (GGT) is a liver enzyme that may indicate disease activity.

Purpose of the Study:

• To evaluate the association between GGT reduction and long-term outcomes in pediatric PSC patients.
• To assess GGT normalization (< 50 IU/L) at one year as a potential surrogate endpoint.
• To investigate the impact of ursodeoxycholic acid (UDCA) treatment on GGT levels and outcomes.

Main Methods:

• A multicenter cohort of 287 pediatric PSC patients was analyzed.
• GGT levels at diagnosis and at one year post-diagnosis were assessed.
• Event-free survival at five years was compared between groups based on GGT normalization and reduction, with or without UDCA treatment.

Main Results:

• While UDCA treatment showed a trend towards lower GGT at one year, 5-year event-free survival was similar between treated and untreated groups.
• Pediatric PSC patients achieving GGT normalization (< 50 IU/L) by one year had significantly better 5-year event-free survival (91% vs. 67%).
• A greater than 75% reduction in GGT within one year also correlated with improved 5-year event-free survival (88% vs. 61%).

Conclusions:

• GGT normalization (< 50 IU/L) or a >75% reduction by one year post-diagnosis is a strong predictor of favorable 5-year outcomes in pediatric PSC.
• GGT demonstrates significant promise as a surrogate endpoint for future clinical trials in pediatric PSC.
• These findings support the use of GGT as an early indicator of treatment response and long-term prognosis in children with PSC.